Imagine if your doctor could see a 'weather forecast' for your heart years before a storm hits. Instead of just looking at your age or smoking habits, this tool scans your DNA and blood markers to find hidden warning signs. It helps doctors treat men and women differently because their bodies react to heart disease in unique ways.
Current heart disease risk models (like SCORE2) are too generic and miss genetic drivers, leading to unexpected strokes or heart attacks in patients who seemed 'low risk'.
A multi-omics prediction model that combines genetic data (PRS) and blood biomarkers to identify high-risk cardiovascular patients.
If you are a drug discovery firm dealing with high failure rates in cardiovascular trials — this project identified 17 potential new drug targets, including HTRA1, that can be used to develop targeted therapies for atherosclerosis.
If you are a clinical laboratory dealing with outdated risk scores like SCORE2 — this project developed a method integrating polygenic risk scores that provides a 10% improvement in accurately classifying high-risk patients.
If you are a health-tech developer dealing with generic health advice — this project identified five distinct plaque types and sex-specific patterns that allow for personalized risk stratification tools.
Based on available project data, there is no specific pricing or cost information provided for the implementation of these models.
The project utilizes the globally largest CAD, PAD, and stroke GWAS information, suggesting the underlying data is scalable, though industrial deployment details are not specified.
Based on available project data, the specific licensing terms for the 17 identified drug targets have not been disclosed.
The project aims to enhance existing tools like SCORE2 by adding polygenic risk and circulating biomarkers to the diagnostic process.
The project period runs from 2023-10-01 to 2027-09-30, with final results expected by September 2027.
The consortium is heavily academic, consisting of 9 partners across 6 countries, with 8 universities and 1 other organization. There are 0 industry partners and 0 SMEs, indicating the project is currently focused on fundamental discovery and validation rather than immediate commercialization.
Contact University of Helsinki (SUOMEN YLIOPISTO) in Finland
Contact us to bridge the gap between these 17 drug targets and your R&D pipeline.
